Trial Profile
A Phase II Open Label, Single Arm Study to Evaluate the Efficacy of Pembrolizumab for Leukoplakia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Erythroleucoplakia; Leucoplakia
- Focus Therapeutic Use
- 13 Jun 2023 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
- 13 Jun 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 23 Jun 2022 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.